Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Debt (2016 - 2025)

Guided Therapeutics' Non-Current Debt history spans 12 years, with the latest figure at $23000.0 for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 51.06% to $23000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $23000.0, a 51.06% decrease, with the full-year FY2025 number at $23000.0, down 51.06% from a year prior.
  • Non-Current Debt hit $23000.0 in Q4 2025 for Guided Therapeutics, down from $29000.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for GTHP hit a ceiling of $586000.0 in Q3 2021 and a floor of $6000.0 in Q1 2021.
  • Historically, Non-Current Debt has averaged $159500.0 across 4 years, with a median of $50000.0 in 2024.
  • Biggest five-year swings in Non-Current Debt: plummeted 98.96% in 2021 and later surged 9366.67% in 2022.
  • Tracing GTHP's Non-Current Debt over 4 years: stood at $22000.0 in 2021, then surged by 277.27% to $83000.0 in 2022, then plummeted by 43.37% to $47000.0 in 2024, then tumbled by 51.06% to $23000.0 in 2025.
  • Business Quant data shows Non-Current Debt for GTHP at $23000.0 in Q4 2025, $29000.0 in Q3 2025, and $35000.0 in Q2 2025.